

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 8-K/A

INTEGRA LIFESCIENCES HOLDINGS CORP

Form 8-K/A

August 06, 2001

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

=====

FORM 8-K/A
(AMENDMENT NO. 1)

=====

CURRENT REPORT

=====

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

AUGUST 2, 2001

Date of report (Date of earliest event reported)

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(exact name of registrant as specified in its charter)

DELAWARE	0-26224	51-0317849
-----	-----	-----
(State or other jurisdiction of incorporation or organization)	Commission File Number	(I.R.S. Employer Identification Number)

311 ENTERPRISE DRIVE, PLAINSBORO, NEW JERSEY 08536

(Address of Principal Executive Offices) (Zip Code)

(609) 275-0500

(Registrant's telephone number, including area code)

NOT APPLICABLE

(Former name or former address, if changed since last report.)

=====

The undersigned Registrant hereby amends Item 5 and the financial page of Exhibit 99.1 of its Current Report on Form 8-K dated August 2, 2001.

ITEM 5. OTHER EVENTS.

On August 2, 2001 Integra LifeSciences Holdings Corporation (Nasdaq: IART) (the "Company") reported its financial results for the second quarter of 2001 in a press release. A copy of the Company's press release has been filed as

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 8-K/A

an exhibit to a Current Report on Form 8-K filed on August 2, 2001.

The press release contained an error in the calculation of basic earnings per share for the three-month period ended June 30, 2001 because it did not include the non-cash dividends associated with the Company's Series B Preferred Stock during that portion of the period in which the Series B Preferred Stock was outstanding. The Series B Preferred Stock was converted into 2,617,800 common shares on June 26, 2001.

The basic earnings per share for the three-month period ended June 30, 2001 was incorrectly reported as \$0.13. The correct basic earnings per share for such period is \$0.12, which includes the effect of the non-cash dividends. All other earnings per share calculations in the press release were calculated and reported correctly.

A revised copy of the financial page of the Company's original press release has been filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(a) and (b) None.

The following document is furnished as an Exhibit to this Current Report on Form 8-K pursuant to Item 601 of Regulation S-K:

99.1 Revised copy of the financial page to the Press Release, dated August 2, 2001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES
HOLDINGS CORPORATION

By: JOHN B. HENNEMAN III

Name: John B. Henneman III
Title: Senior Vice President,
Chief Administrative Officer
and Secretary

Date: August 6, 2001

EXHIBIT INDEX

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 8-K/A

EXHIBIT NO.	DOCUMENT DESCRIPTION
99.1	Revised copy of the financial page to the Press Release, dated August 2, 2001.